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optimal management of these patients, nor is there reliable information on the cost 
and quality-of-life implications of recurrence. Methods: A patient management 
pathway for one- or two-step abdominal wall reconstructions was developed using 
available literature and surgeon input, and was evaluated using a pilot paper-based 
questionnaire, which was sent to European surgeons with relevant experience. Based 
on responses, a revised version of the questionnaire was created in anonymised iPad 
format for use at surgical conferences. Both the questionnaire and iPad survey aimed 
to elicit surgical decision-making data regarding types of repair materials used, such 
as synthetic or biological meshes and the characteristics of these that determine sur-
geon choices. Important additional factors, including co-morbidities, safety, contami-
nation, and risk of recurrence, were included in the questionnaire, as well as the likely 
length of hospital stay. Use of the Ventral Hernia Working Group guidelines was also 
questioned. The second stage of this process will collect retrospective resource use 
data from patient records to determine patterns of care and cost that could improve 
surgical decision-making and patient outcomes. Results: To date, 16 paper-based 
questionnaires and 5 iPad surveys have been completed. Surgeons from the UK (7), 
Belgium (3), Germany (3) the Netherlands (2) and Italy (1) completed the paper-based 
questionnaire. ConClusions: There is sufficient agreement amongst surgeons to 
produce a patient management pathway, and additional results from ongoing data 
collection will improve confidence in the consensus.
ReseaRch On MethOds – Patient-Reported Outcomes studies
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objeCtives: Chronic urticaria (CU) (or chronic hives) can be inducible or sponta-
neous (also known as idiopathic urticaria) (CSU/CIU). Data supporting the impact 
of CSU/CIU on patients and comparison with other dermatological diseases are 
scarce. This study evaluated humanistic burden associated with CU relative to pso-
riasis (PsO) and different severity of PsO among the adults in 5 European (France, 
Germany, Italy, Spain and UK) countries. Methods: Data come from diagnosed 
CU (proxy for CSU) and PsO patients collected in the National Health and Wellness 
Survey (NHWS). Humanistic burden was measured through the mental and physi-
cal component score (MCS, PCS) of the SF-36v2 and SF-6D health utility score. 
Self-reported anxiety, depression and sleep difficulty were also assessed. NHWS 
collects data on PsO severity but not on CU severity. Multiple linear or logistic 
regressions was used to compare outcomes between patients with CU vs. overall 
PsO (included all severity levels) and CU vs. moderate-severe-PsO, controlling for 
patient characteristics. Results: Study included 769 CU patients and 7,857 PsO 
patients (26.9% moderate-severe). CU patients had lower (worse) MCS (mean±SE, 
42.2±0.39 vs. 44.6±0.16), PCS (45.2±0.34 vs. 46.8±0.14) and SF-6D score (0.65±0.005 
vs. 0.68±0.002) than overall PsO (all p< 0.001). Scores for moderate-severe-PsO 
were 43.2±0.25 (p< 0.05), 45.7±0.22 (p= NS) and 0.667±0.003 (p< 0.05) respectively. 
CU patients had higher adjusted odds of anxiety, depression and sleep difficulties 
than overall PsO [odds ratio (OR):1.63, 1.34 and 1.56, respectively, all p< 0.01]. There 
was no significant difference between moderate-severe-PsO (OR: 1.45, 1.12, and 
1.36, respectively) and CU patients for the same parameters. ConClusions: CU 
and PsO have a negative impact on patients’ quality of life. CU patients report 
significantly higher impairment and more psychological complaints than overall 
PsO patients. When compared to moderate-severe-PsO, patients with CU still have 
a significantly slightly higher impairment in mental status and lower utility and 
similar physical impairment and psychological complaints.
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objeCtives: The Self-Assessment of Treatment Version II (SAT-II) instrument has 
three versions: baseline; follow-up (FU); and last-visit versions. Baseline version 
measures pain level (one item) and impact of pain (six items). Follow-up and last-
visit versions measure improvement in the impact or level of pain due to treat-
ment. Last-visit also includes two items about treatment preferences. This study 
explored scoring of the SAT-II (baseline and last-visit). Scores were also assessed 
for their responsiveness to change. Methods: Data from 369 patients (42% female; 
mean age= 63) with painful diabetic peripheral neuropathy from a randomised, 
double-blind placebo-controlled trial (STEP) were used to test baseline and last-visit 
versions. Item-to-item spearman correlations and spearman correlations between 
summary scores and Brief Pain Inventory-Diabetic Neuropathy pain severity score 
(PSS) were tested. Factor analysis was conducted on the six impact items to develop 
a scoring algorithm (baseline or last-visit summary score). Analysis of variance 
measured responsiveness to treatment responder status as defined by PSS (both 
≥ 30% & ≥ 50% reduction from baseline) and Patient Global Impression of Change 
(PGIC; much/very much improved). Results: A single-factor structure for the six 
impact items was demonstrated for baseline and last-visit. Item-to-item correla-
tions (baseline: correlation (r)= 0.33 to 0.75; last-visit: r= 0.52 to 0.89) and correla-
tions between a sum of the impact items and PSS were significant for baseline 
(r= 0.39, p= 0.001) and last-visit (r= -0.46, p= 0.0001). A mean summary score of the 
impact items discriminated (all p< 0.0001) between non-responders and respond-
ers, respectively for each definition as follows: ≥ 30%, 0.6 (SD 0.9) vs 1.9(1.3); ≥ 50%, 
0.8 (1.0) vs. 2.3 (1.3); and PGIC, 0.6 (0.7) vs. 2.3 (1.2). ConClusions: The six impact 
items of the SAT-II can be scored as a summary measure on both the baseline and 
copula families available and conditional version of the Sklar’s theorem provides 
theoretical background of using covariates for copula parameters. The models 
were fitted by optimizing the pseudo maximum likelihood numerically using 
the R statistical software. Results: The associations between several biomarker 
couples were measured by correlation. Pearson’s (ρ ) and Kendall’s (τ ) correla-
tions were ρ = 0.55 and τ = 0.4 for VAS-HAQ and ρ = 0.66 and τ = 0.48 for VAS-DAS28. 
Additionally, the bivariate/trivariate dependences were modelled with or without 
assuming further covariates as e.g. age at first RA diagnosis or the type of therapy 
etc. ConClusions: The association among biomarkers is strongly positive, how-
ever the association within different subgroups of the RA patients can be signifi-
cantly different too. These differences should be taken into account in any further 
statistical analysis as not only the marginal distributions of biomarkers but their 
dependence structure can be instrumental in modelling too.
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objeCtives: To validate health economic (HE) models by means of statistical 
comparison of model outcomes against empirical observations. Such a compari-
son is structured and the applicability of several existing validation techniques 
is discussed, with a special focus on statistical testing. When standard methods 
(95%-confidence intervals) are used several problems, both of a technical and philo-
sophical nature, are encountered. These problems are discussed. A new statisti-
cal approach is consequently proposed. Methods: The proposed method can be 
applied to validate HE models when the uncertainty around the input parameters 
of the model is assessed via probabilistic sensitivity analysis (PSA). It is based on 
the idea of establishing a level of accuracy in advance for the empirical observa-
tions and model outcomes should meet. If the model result falls within the limits 
determined by the pre-required accuracy, then the model result is considered valid. 
The number of valid results obtained in a PSA defines a measure of the reliability 
of the model. Embodying the method in a Bayesian framework allows defining 
such a reliability measure with statistical properties. Results: Existing approaches 
suffer from technical and interpretational problems. In addition, these methods 
are lacking a measure of overall reliability. Our new method (1) departs from clas-
sical statistical techniques, circumventing the noted problems, (2) can be used for 
both cohort and patient-level models and (3) makes use of all PSA outcomes. The 
method is demonstrated with the help of a case study in a published diabetes model 
(MICADO). ConClusions: Standard statistical techniques have to be applied very 
carefully on the comparison of model outcomes to empirical observations. They 
suffer from several problems. A new promising Bayesian approach is proposed that 
solves some of these issues. Our new method allows stepwise validation of the 
model as new data becomes available, which may increase the model’s validation 
status.
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objeCtives: Pharmaceuticals are usually granted a marketing authorisation on 
the basis of randomised controlled trials (RCTs). Occasionally the efficacy of a 
treatment is assessed without a randomised comparator group (either active or 
placebo). Our objective was to identify and develop a taxonomic account of eco-
nomic modelling approaches for pharmaceuticals approved without randomised 
control data. Methods: We searched PubMed, ISPOR Scientific Presentations 
and the website of UK health technology assessment (HTA) bodies for assess-
ments of the 75 indications granted a marketing authorisation by the FDA or 
EMA from Jan-1999 to May-2014 without RCT data. The outcome of interest was 
the approach to modelling efficacy data. Results: Fifty-one unique models 
were identified based on 29 peer-reviewed articles, 15 ISPOR abstracts, and 30 
health technology appraisals (HTAs). The majority of models (43/51) were based 
on ‘historical controls’ – comparisons to previous meta-analysis or pooling of tri-
als (5), individual trials (19), registries/case series (14), or expert opinion (7). The 
majority of drugs granted a marketing authorisation without a RCT had not been 
evaluated in a published economic model (45/75), with a low rate of submission 
to UK HTA agencies (28/98). ConClusions: There is considerable variation in 
the quality of models constructed for drugs granted a marketing authorisation 
without a RCT. The most common approach is of a naïve comparisons to historical 
data (using other trials/registry data as a control group), with considerable scope 
for bias.
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objeCtives: Complex abdominal wall reconstruction has been a challenging issue 
for surgeons for many years, with many factors affecting surgical decision-making 
and patient outcomes. In particular, complex procedures for ventral hernia repair 
represent a huge healthcare burden, particularly if two-step rather than one-step 
reconstruction is used. Effective abdominal wall reinforcement is among the goals of 
patient management. At present, there appears to be no consistent pathway for the 
